All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
The MDS Hub Steering Commitee met on May 5, 2022. The recorded discussion was chaired by Theo de Witte, and featured Rena Buckstein, and Yasushi Miyazaki. The topic of this discussion, “How do we treat high-risk patients outside of a clinical trial?”, was identified as an unmet educational need within MDS treatment.
How do we treat high-risk patients outside of a clinical trial?
De Witte discusses approaches to treat high-risk patients, including following the current guidelines in MDS treatment, and potential new drugs that may become approved by the U.S. Food and Drug Administration (FDA). Buckstein discusses the use of hypomethylating agents, and what factors she considers when treating patients with these drugs, such as cytotoxicity. Miyazaki talks about using azacitadine in high-risk patients, following the Japanese guidelines.
What patient factors should we consider for intermediate- and high-risk patients beyond the IPSS-R score?
The MDS Hub Steering Commitee met on May 5, 2022. The recorded discussion was chaired by Rena Buckstein, and featured Theo de Witte, Silvia...
Outcomes of patients with CMML treated with hypomethylating agents
Hypomethylating agents (HMAs) currently remain the only approved drugs for the management of chronic myelomonocytic leukemia (CMML), with prospective, randomized controlled trials...
Subscribe to get the best content related to MDS delivered to your inbox